NCT06417697Not yet recruiting
A Phase 1b Study to Evaluate the Safety of XEN-101
A Phase 1b, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Effects of XEN-101 on Safety, Tolerability, and Pharmacodynamics in Subjects With Obesity
Xeno BiosciencesPhase 1ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Obesity
- Drug/Device/Intervention
- XEN-101
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Xeno Biosciences
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Jun 01, 2024
- End date
- Sep 01, 2024
- Enrollment
- 32 participants
Primary outcome
Incidence of treatment emergent adverse events (safety and tolerability),Effect on body weight
Summary
This Phase 1b study will evaluate the effects of XEN-101 in subjects with obesity
ICD-10 classifications
ObesityOther obesityObesity, unspecifiedObesity due to excess caloriesObesity and other hyperalimentation
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06417697
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06417697 through Pure Global AI's free database. This Phase 1 trial is sponsored by Xeno Biosciences and is currently Not yet recruiting. The study focuses on Obesity. Target enrollment is 32 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.